Literature DB >> 11932393

Avian bic, a gene isolated from a common retroviral site in avian leukosis virus-induced lymphomas that encodes a noncoding RNA, cooperates with c-myc in lymphomagenesis and erythroleukemogenesis.

Wayne Tam1, Stephen H Hughes, William S Hayward, Peter Besmer.   

Abstract

bic is a novel gene identified at a common retroviral integration site in avian leukosis virus-induced lymphomas and has been implicated as a collaborator with c-myc in B lymphomagenesis. It lacks an extensive open reading frame and is believed to function as an untranslated RNA (W. Tam, Gene 274:157-167, 2001; W. Tam, D. Ben-Yehuda, and W. S. Hayward, Mol. Cell. Biol. 17:1490-1502, 1997). The oncogenic potential of bic, particularly its ability to cooperate with c-myc in oncogenesis, was tested directly by expressing c-myc and bic, either singly or in pairwise combination, in cultured chicken embryo fibroblasts (CEFs) and in chickens using replication-competent retrovirus vectors. Coexpression of c-myc and bic in CEFs caused growth enhancement of cells. Most importantly, chick oncogenicity assays demonstrated that bic can cooperate with c-myc in lymphomagenesis and erythroleukemogenesis. The present study provides direct evidence for the involvement of untranslated RNAs in oncogenesis and provides further support for the role of noncoding RNAs as riboregulators.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11932393      PMCID: PMC155062          DOI: 10.1128/jvi.76.9.4275-4286.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

Review 1.  Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector.

Authors:  J M Adams; A W Harris; A Strasser; S Ogilvy; S Cory
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

2.  High-frequency transduction of c-erbB in avian leukosis virus-induced erythroblastosis.

Authors:  B D Miles; H L Robinson
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

3.  A single rearrangement event generates most of the chicken immunoglobulin light chain diversity.

Authors:  C A Reynaud; V Anquez; A Dahan; J C Weill
Journal:  Cell       Date:  1985-02       Impact factor: 41.582

4.  Genetic determinants of neoplastic diseases induced by a subgroup F avian leukosis virus.

Authors:  M C Simon; W S Neckameyer; W S Hayward; R E Smith
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

5.  c-erbB activation in avian leukosis virus-induced erythroblastosis: multiple epidermal growth factor receptor mRNAs are generated by alternative RNA processing.

Authors:  R G Goodwin; F M Rottman; T Callaghan; H J Kung; P A Maroney; T W Nilsen
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

6.  Synergism of v-myc and v-Ha-ras in the in vitro neoplastic progression of murine lymphoid cells.

Authors:  R C Schwartz; L W Stanton; S C Riley; K B Marcu; O N Witte
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

7.  c-erbB activation in avian leukosis virus-induced erythroblastosis: clustered integration sites and the arrangement of provirus in the c-erbB alleles.

Authors:  M A Raines; W G Lewis; L B Crittenden; H J Kung
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

8.  c-erbB activation in ALV-induced erythroblastosis: novel RNA processing and promoter insertion result in expression of an amino-truncated EGF receptor.

Authors:  T W Nilsen; P A Maroney; R G Goodwin; F M Rottman; L B Crittenden; M A Raines; H J Kung
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

9.  Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development.

Authors:  A Leder; P K Pattengale; A Kuo; T A Stewart; P Leder
Journal:  Cell       Date:  1986-05-23       Impact factor: 41.582

10.  Activation of c-erbB in avian leukosis virus-induced erythroblastosis leads to the expression of a truncated EGF receptor kinase.

Authors:  I Lax; R Kris; I Sasson; A Ullrich; M J Hayman; H Beug; J Schlessinger
Journal:  EMBO J       Date:  1985-12-01       Impact factor: 11.598

View more
  42 in total

Review 1.  miRNAs in normal and malignant B cells.

Authors:  Ai Kotani; Ratanakanit Harnprasopwat; Takae Toyoshima; Toyotaka Kawamata; Arinobu Tojo
Journal:  Int J Hematol       Date:  2010-07-08       Impact factor: 2.490

2.  Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155.

Authors:  Rebecca L Skalsky; Mark A Samols; Karlie B Plaisance; Isaac W Boss; Alberto Riva; M Cecilia Lopez; Henry V Baker; Rolf Renne
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

3.  Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155.

Authors:  Suhwan Chang; Rui-Hong Wang; Keiko Akagi; Kyung-Ae Kim; Betty K Martin; Luca Cavallone; Diana C Haines; Mark Basik; Phuong Mai; Elizabeth Poggi; Claudine Isaacs; Lai M Looi; Kein S Mun; Mark H Greene; Stephen W Byers; Soo H Teo; Chu-Xia Deng; Shyam K Sharan
Journal:  Nat Med       Date:  2011-09-25       Impact factor: 53.440

4.  MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice.

Authors:  Fen Du; Fang Yu; Yuzhen Wang; Yvonne Hui; Kevin Carnevale; Mingui Fu; Hong Lu; Daping Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-02-06       Impact factor: 8.311

Review 5.  MicroRNAs of the immune system: roles in inflammation and cancer.

Authors:  Jan Davidson-Moncada; F Nina Papavasiliou; Wayne Tam
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

6.  miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model.

Authors:  Sukhinder K Sandhu; Stefano Volinia; Stefan Costinean; Marco Galasso; Reid Neinast; Ramasamy Santhanam; Mark R Parthun; Danilo Perrotti; Guido Marcucci; Ramiro Garzon; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-19       Impact factor: 11.205

Review 7.  Clinical relevance of KRAS in human cancers.

Authors:  Sylwia Jancík; Jirí Drábek; Danuta Radzioch; Marián Hajdúch
Journal:  J Biomed Biotechnol       Date:  2010-06-07

Review 8.  MicroRNAs in cancer: small molecules with a huge impact.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

9.  MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-transformed T lymphocytes.

Authors:  Klemens Pichler; Grit Schneider; Ralph Grassmann
Journal:  Retrovirology       Date:  2008-11-12       Impact factor: 4.602

10.  Oncoviruses and Pathogenic MicroRNAs in Humans.

Authors:  Yoichi Robertus Fujii
Journal:  Open Virol J       Date:  2009-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.